- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 86 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 161 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.05. | TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall | 2 | Seeking Alpha | ||
| 02.05. | TransCode Therapeutics approves reverse stock split to meet Nasdaq rules | 2 | Investing.com | ||
| 02.05. | TransCode Therapeutics genehmigt Aktienzusammenlegung zur Einhaltung der NASDAQ-Regeln | 3 | Investing.com Deutsch | ||
| 02.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 93 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
| 01.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 75 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen | |
| 01.05. | EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug | 3 | Benzinga.com | ||
| 30.04. | Transcode Therapeutics, Inc. - 10-K/A, Annual Report | 4 | SEC Filings | ||
| 21.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | 13 | SEC Filings | ||
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | 6 | SEC Filings | ||
| 31.03. | Transcode Therapeutics, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 5 | SEC Filings | ||
| 27.03. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 | 154 | PR Newswire | First patient in Cohort four has been treated with TTX-MC138
Ten patients have been treated with TTX-MC138 at escalating dose levels
Additional patients being... ► Artikel lesen | |
| 25.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | TransCode Therapeutics Announces $10M Stock And Warrant Offering | 1 | RTTNews | ||
| 24.03. | TransCode Therapeutics stock slides after announces to raise $10M securities offering | 5 | Seeking Alpha | ||
| 21.03. | TransCode Therapeutics Stock Surges 85% | 15 | RTTNews | ||
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 622 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 13.03. | TransCode Therapeutics Advances Phase I Trial Of RNA Cancer Therapy | 5 | RTTNews |
Seite:
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,80 | +0,49 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| QIAGEN | 37,615 | +0,36 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| NOVAVAX | 5,607 | +5,16 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,100 | +1,41 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.05.2025.ISIN NameGB00BYQ94H38 ONCIMMUNE... ► Artikel lesen | |
| BRAIN BIOTECH | 2,130 | +1,91 % | Brain Biotech: Schwaches Jahresviertel | Im zweiten Quartal sinkt der Umsatz bei Brain Biotech um 16 Prozent auf 12,12 Millionen Euro. Das bereinigte EBITDA steht bei -0,36 Millionen Euro. Für das Gesamtjahr nimmt die Gesellschaft ihre Prognose... ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | 0,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,750 | +3,55 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,780 | -8,55 % | COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures... ► Artikel lesen | |
| GENMAB | 175,00 | +0,81 % | Genmab A/S: Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress | Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab... ► Artikel lesen | |
| XOMA ROYALTY | 24,800 | +3,33 % | XOMA Royalty GAAP EPS of $0.06, revenue of $15.91M | ||
| T2 BIOSYSTEMS | 0,107 | +3,38 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,780 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial | Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| ORAGENICS | 0,196 | 0,00 % | Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia | SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.